57.04 0.00 (0.01%)
After hours: 4:26PM EST
|Bid||57.05 x 800|
|Ask||57.06 x 1400|
|Day's range||56.84 - 57.38|
|52-week range||43.57 - 58.01|
|Beta (3Y monthly)||0.61|
|PE ratio (TTM)||23.17|
|Forward dividend & yield||1.25 (2.19%)|
|1y target est||62.73|
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
European shares clocked their best day in over a week on Friday, as upbeat jobs data from the United States and a surprise bounce in Chinese manufacturing tempered nerves around slowing global growth. U.S. job growth slowed less than expected in October, while a private business survey indicated that China's factory activity unexpectedly expanded at the fastest pace in more than two years last month. The latest data out of China is in contrast to an official survey published on Thursday, which had factory activity shrinking for the sixth straight month in October.
Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs. Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. The world's largest maker of diabetes drugs is betting on new treatments, including a first-of-its-kind tablet, to offset pricing pressure from competing insulins and U.S. lawmakers, who have been critical of rising drug costs.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
Does the October share price for Novo Nordisk A/S (CPH:NOVO B) reflect what it's really worth? Today, we will estimate...